Search research articles
Contact Us
Filters
Showing results (651-660 of 706) with videos related to
Page
of 71
Sort By:
American Heart Journal
|
January 5, 2021
Risk markers of incident atrial fibrillation in patients with coronary heart disease
Maria Tomasdottir, Claes Held, Nermin Hadziosmanovic, et al.
European Heart Journal
|
April 3, 2009
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
Deepak L Bhatt, Eric D Peterson, Robert A Harrington, et al.
The American Journal of Cardiology
|
October 24, 2006
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
Pierluigi Tricoci, Eric D Peterson, Jyotsna Mulgund, et al.
The New England Journal of Medicine
|
August 29, 2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Christopher P Cannon, Deepak L Bhatt, Jonas Oldgren, et al.
JAMA Cardiology
|
May 19, 2021
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry
Adam N Berman, David W Biery, Curtis Ginder, et al.
European Journal of Preventive Cardiology
|
October 28, 2025
Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic Disease
Andre Zimerman, Frederick K Kamanu, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology
|
September 11, 2024
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF
Ankeet S Bhatt, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Page
of 71
Search research articles
Search
Showing results (651-660 of 706) with videos related to
Sort By:
Page
of 71
American Heart Journal
|
January 5, 2021
Risk markers of incident atrial fibrillation in patients with coronary heart disease
Maria Tomasdottir, Claes Held, Nermin Hadziosmanovic, et al.
European Heart Journal
|
April 3, 2009
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
Deepak L Bhatt, Eric D Peterson, Robert A Harrington, et al.
The American Journal of Cardiology
|
October 24, 2006
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
Pierluigi Tricoci, Eric D Peterson, Jyotsna Mulgund, et al.
The New England Journal of Medicine
|
August 29, 2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Christopher P Cannon, Deepak L Bhatt, Jonas Oldgren, et al.
JAMA Cardiology
|
May 19, 2021
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry
Adam N Berman, David W Biery, Curtis Ginder, et al.
European Journal of Preventive Cardiology
|
October 28, 2025
Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic Disease
Andre Zimerman, Frederick K Kamanu, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology
|
September 11, 2024
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF
Ankeet S Bhatt, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Page
of 71